Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Targeted therapy (TT) in patients with KRAS wildtype (WT) pancreatic ductal adenocarcinoma (PDAC) produces durable response.
Authors
Maahum Mehdi
Medical College of Wisconsin, Wauwatosa, WI
Maahum Mehdi , Kaitlin Annunzio , Bradley W. Taylor , Aniko Szabo , Aditya V. Shreenivas , Sakti Chakrabarti , James P. Thomas , Susan Tsai , Kathleen K. Christians , Douglas B. Evans , Callisia Clarke , William A. Hall , Beth Erickson , Bicky Thapa , Gulrayz Ahmed , Ben George , Mandana Kamgar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
DOI
10.1200/JCO.2022.40.4_suppl.596
Abstract #
596
Poster Bd #
B8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
PASS-01: Pancreatic adenocarcinoma signature stratification for treatment–01.
First Author: Jennifer J. Knox
Poster
2024 ASCO Annual Meeting
Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.
First Author: Teresa Macarulla
Poster
2023 ASCO Annual Meeting
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.
First Author: Aaron Ciner
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.
First Author: Michele Reni